Ombitasvir

Chemical compound

Ombitasvir
Clinical data

Trade names	Viekira Pak, Viekira XR (with ombitasvir, paritaprevir, ritonavir and dasabuvir), Technivie (with ombitasvir, paritaprevir, and ritonavir)
Other names	ABT-267
License data	EU EMA: by INN
Routes of administration	By mouth (tablets)
Legal status
Legal status	US: ℞-only
Pharmacokinetic data
Bioavailability	Not determined
Protein binding	~99.9%
Metabolism	Amide hydrolysis followed by oxidation
Onset of action	~4 to 5 hours
Elimination half-life	21 to 25 hours
Excretion	Mostly with feces (90.2%)
Identifiers
IUPAC name Dimethyl N,N′-{[(2S,5S)-1-(4-tert-butylphenyl)pyrrolidene-2,5-diyl]-bis-{[(4,1-phenyleneazanediyl)carbonyl] [(2S)-pyrrolidine-2,1-diyl]}[(2S)-3-methyl-1-oxobutane-1,2-diyl])}biscarbamate
CAS Number	1258226-87-7
PubChem CID	54767916
ChemSpider	31136214
UNII	2302768XJ8
KEGG	D10576^Y
ChEBI	CHEBI:85183^Y
Chemical and physical data
Formula	C₅₀H₆₇N₇O₈
Molar mass	894.127 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES CC(C)[C@@H](C(=O)N1CCC[C@H]1C(=O)Nc2ccc(cc2)[C@@H]3CC[C@H](N3c4ccc(cc4)C(C)(C)C)c5ccc(cc5)NC(=O)[C@@H]6CCCN6C(=O)[C@H](C(C)C)NC(=O)OC)NC(=O)OC
InChI InChI=1S/C50H67N7O8/c1-30(2)42(53-48(62)64-8)46(60)55-28-10-12-40(55)44(58)51-35-20-14-32(15-21-35)38-26-27-39(57(38)37-24-18-34(19-25-37)50(5,6)7)33-16-22-36(23-17-33)52-45(59)41-13-11-29-56(41)47(61)43(31(3)4)54-49(63)65-9/h14-25,30-31,38-43H,10-13,26-29H2,1-9H3,(H,51,58)(H,52,59)(H,53,62)(H,54,63)/t38-,39-,40-,41-,42-,43-/m0/s1 Key:PIDFDZJZLOTZTM-KHVQSSSXSA-N

Ombitasvir is an antiviral drug for the treatment of hepatitis C virus (HCV) infection by AbbVie. In the United States, it is approved by the Food and Drug Administration for use in combination with paritaprevir, ritonavir and dasabuvir in the product Viekira Pak for the treatment of HCV genotype 1,^[1]^[2] and with paritaprevir and ritonavir in the product Technivie for the treatment of HCV genotype 4.^[3]^[4]

Ombitasvir is an NS5A inhibitor that acts by inhibiting the HCV protein NS5A.^[5]

References

^ "VIEKIRA PAK™ (ombitasvir, paritaprevir and ritonavir tablets; dasabuvir tablets), for Oral Use. Full Prescribing Information" (PDF). AbbVie Inc., North Chicago, IL 60064. Retrieved 30 July 2015.
^ "FDA approves Viekira Pak to treat hepatitis C". Food and Drug Administration. December 19, 2014.
^ "TECHNIVIE™ (ombitasvir, paritaprevir and ritonavir) Tablets, for Oral Use. Full Prescribing Information" (PDF). AbbVie Inc., North Chicago, IL 60064. Archived from the original (PDF) on 19 January 2019. Retrieved 28 July 2015.
^ "FDA approves Technivie for treatment of chronic hepatitis C genotype 4". Food and Drug Administration. July 24, 2015.
^ Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, Crawford D, et al. (April 2014). "Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin" (PDF). The New England Journal of Medicine. 370 (17): 1594–603. doi:10.1056/NEJMoa1315722. PMID 24720703.

Grebely J, Puoti M, Wedemeyer H, Cooper C, Sulkowski MS, Foster GR, et al. (November 2018). "Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in Patients With Chronic Hepatitis C Virus Genotype 1 Infection Receiving Opioid Substitution Therapy: A Post Hoc Analysis of 12 Clinical Trials". Open Forum Infectious Diseases. 5 (11): ofy248. doi:10.1007/s15010-018-1157-x. OCLC 1105037362. PMC 6222025. PMID 30430131.
Petta S, Marzioni M, Russo P, Aghemo A, Alberti A, Ascione A, et al. (June 2017). "Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study". The Lancet. Gastroenterology & Hepatology. 2 (6): 427–434. doi:10.1016/S2468-1253(17)30048-1. hdl:11390/1119739. PMID 28497758.

NS3/4A protease inhibitors (–previr)	Asunaprevir Boceprevir^‡ Ciluprevir^§ Danoprevir^† Faldaprevir^‡ Glecaprevir Grazoprevir Narlaprevir Paritaprevir Simeprevir Sovaprevir^† Telaprevir^‡ Vaniprevir Vedroprevir^§ Voxilaprevir
NS5A inhibitors (–asvir)	Daclatasvir^# Elbasvir Ledipasvir Odalasvir^† Ombitasvir Pibrentasvir Ravidasvir^† Ruzasvir^† Samatasvir^† Velpatasvir
NS5B RNA polymerase inhibitors (–buvir)	Beclabuvir^† Bemnifosbuvir^† Dasabuvir^# Deleobuvir^§ Filibuvir^§ GS-6620^§ IDX-184^§ Setrobuvir^§ Sofosbuvir^# Tegobuvir^§ TMC-647055^§ Radalbuvir^† Uprifosbuvir^†
Combination drugs	Elbasvir/grazoprevir Glecaprevir/pibrentasvir Ledipasvir/sofosbuvir^# Ombitasvir/paritaprevir/ritonavir^# Sofosbuvir/daclatasvir Sofosbuvir/velpatasvir^# Sofosbuvir/velpatasvir/voxilaprevir

Anti-influenza agents

Multiple/general

Interferon	Interferon alfa 2b Peginterferon alfa-2a^# Peginterferon alfa-2b^#
3CL protease inhibitors (–trelvir)	Ensitrelvir^† Lufotrelvir Nirmatrelvir^† (+ritonavir)^† Rupintrivir Simnotrelvir (+ritonavir^†)
RNA pol inhibitors	CMX521^§ Deuremidevir^† Favipiravir Galidesivir^† GS-441524^§ Remdesivir MK-608^§ Mericitabine^† Molnupiravir NITD008^§ Ribavirin^# Taribavirin^† Triazavirin Valopicitabine^†
Multiple/Unknown/Other	EICAR^§ Merimepodib^§ Moroxydine Presatovir^†